5:09 PM
 | 
Apr 01, 2013
 |  BC Extra  |  Clinical News

Clavis discontinues development of elacytarabine

Clavis Pharma ASA (OSE:CLAVIS) discontinued development of elacytarabine after the compound missed the primary endpoint of improving median overall survival (OS) vs. investigator's choice of therapy in the Phase III CLAVELA trial to treat late-stage acute myelogenous leukemia (AML). The open-label,...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >